IR@PKUHSC  > 北京大学第一临床医学院  > 泌尿外科
学科主题临床医学
Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers
He Zhisong1,2,3; Guo Gang4; Zhang Cuijian1,2,3; Li Xuesong1,2,3; Fu Weijun4; Jin Jie1,2,3; Zhang Xu4; Zhou Liqun1,2,3
关键词Sunitinib Renal Cell Carcinoma Metastasis Efficacy Targeted Therapy
刊名CHINESE MEDICAL JOURNAL
2014-04-20
DOI10.3760/cma.j.issn.0366-6999.20132411
127期:8页:1450-1453
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]INTERFERON-ALPHA ; TRIAL ; SURVIVAL ; THERAPY
英文摘要

Background The advent of targeted therapy has proved a milestone in the history of metastatic renal cell carcinoma treatment, and several guidelines now recommend sunitinib as first- or second-line treatment. But little is known about its efficacy in Asian patients. The aim of this article was to evaluate the efficacy of sunitinib monotherapy in patients with metastatic renal cell carcinoma treated at two Chinese centers.

Methods One hundred and forty-one patients with metastatic renal cell carcinoma were included in the study. Of them, 119 patients received single-agent sunitinib as first-line therapy and the remaining 22 patients received it as second-line therapy. One hundred and twenty patients received sunitinib in a dosage of 50 mg orally once daily on a 4-2 schedule (4 weeks on treatment, 2 weeks off), while 21 patients received 37.5 mg/day continuously until either disease progression or unacceptable toxicity occurred. The overall response rate, survival outcomes, and safety were evaluated.

Results Over a median follow-up time of 23 months (16 cycles; range 2-45 months), complete responses, partial responses, and stable disease lasting two cycles or longer were achieved in 2.8%, 24.1%, and 60.3% of patients respectively (objective response rate 26.9%; overall benefit 87.2%). The median progression-free survival was 14.2 months (range 3-39 months). During the study, 53 patients died and the median survival time was 13.5 months (range 7-25 months). Dose modification or treatment interruption due to adverse events was required in 36.9% of the patients. The most common adverse events were hand foot syndrome (71.4%), thrombocytopenia (68.8%), hypertension (47.1%), and fatigue (46.3%).

Conclusion Sunitinib had a favorable efficacy/tolerability profile in Chinese patients with metastatic renal cell carcinoma.

语种英语
WOS记录号WOS:000335936700011
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53636
专题北京大学第一临床医学院_泌尿外科
作者单位1.Peking Univ, Hosp 1, Dept Urol, Beijing 100034, Peoples R China
2.Peking Univ, Inst Urol, Beijing 100034, Peoples R China
3.Natl Urol Canc Ctr, Beijing 100034, Peoples R China
4.Peoples Liberat Army Gen Hosp, Dept Urol Surg, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
He Zhisong,Guo Gang,Zhang Cuijian,et al. Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers[J]. CHINESE MEDICAL JOURNAL,2014,127(8):1450-1453.
APA He Zhisong.,Guo Gang.,Zhang Cuijian.,Li Xuesong.,Fu Weijun.,...&Zhou Liqun.(2014).Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers.CHINESE MEDICAL JOURNAL,127(8),1450-1453.
MLA He Zhisong,et al."Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers".CHINESE MEDICAL JOURNAL 127.8(2014):1450-1453.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[He Zhisong]的文章
[Guo Gang]的文章
[Zhang Cuijian]的文章
百度学术
百度学术中相似的文章
[He Zhisong]的文章
[Guo Gang]的文章
[Zhang Cuijian]的文章
必应学术
必应学术中相似的文章
[He Zhisong]的文章
[Guo Gang]的文章
[Zhang Cuijian]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。